Clinical Trials Browser

INDUSTRY × Neoplasms, Plasma Cell × 90 days × Clear all

NCT06152575 2026-04-16

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07529782 2026-04-14

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07354555 2026-03-20

MMExFFPE

Not yet recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02952508 2026-03-18

CLOVER-WaM

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT04328662 2026-03-04

A Study of Ninlaro in Real World Clinical Practice in China

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell